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a  b  s  t  r a  c t
The Standards  for  Reporting  Interventions  in Clinical  Trials  of Acupuncture (STRICTA)  were  published  in
five  journals  in 2001 and 2002. These  guidelines,  in the  form  of a  checklist  and explanations  for  use by
authors  and  journal  editors, were designed  to improve  reporting  of acupuncture  trials,  particularly  the
interventions,  thereby  facilitating their  interpretation  and replication. Subsequent reviews  of the  appli-
cation  and impact of STRICTA have  highlighted the  value  of STRICTA  as  well  as  scope for  improvements
and  revision.
© 2016  Published by Elsevier  GmbH.  This  is  an open  access article  under  the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
To manage the revision process a  collaboration between the
STRICTA Group, the CONSORT Group, and the Chinese Cochrane
Centre was developed in  2008. An expert panel with 47 participants
was convened that provided electronic feedback on a  revised draft
of the checklist. At  a  subsequent face-to-face meeting in Freiburg, a
group of 21 participants further revised the STRICTA checklist and
planned dissemination.
The new STRICTA checklist, which is an official extension of
CONSORT, includes six items and 17 sub-items. These set out
reporting guidelines for the acupuncture rationale, the details of
 This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original author and source are cred-
ited. In order to encourage dissemination of the  STRICTA Statement, this article
is  freely accessible on  the Acupuncture and Related Therapies web site and
will be also published in Acupuncture in Medicine, Australian Journal of Acupunc-
ture and Chinese Medicine, Journal of  Alternative & Complementary Medicine,
Journal of Evidence-based Medicine, Medical Acupuncture and PLoS Medicine. For
details on citing and using STRICTA guidelines and the CONSORT statement,
see http://www.stricta.info/citations.html or http://www.consort-statement.org/
consort-statement/citing-and-using-consort/ respectively.
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needling, the treatment regimen, other components of  treatment,
the practitioner background, and the control or comparator inter-
ventions. In addition, and as part of this revision process, the
explanations for each item have been elaborated, and examples
of good reporting for each item are provided. In addition, the word
“controlled” in STRICTA is  replaced by “clinical”, to  indicate that
STRICTA is  applicable to a broad range of clinical evaluation designs,
including uncontrolled outcome studies and case reports.
It is  intended that the revised STRICTA, in conjunction with both
the main CONSORT Statement and extension for nonpharmacologic
treatment, will raise the quality of reporting of clinical trials of
acupuncture.
1. Introduction
The STRICTA (Standards for Reporting Interventions in  Clin-
ical Trials of Acupuncture) reporting guidelines, first published
in 2001 [1–9], were designed to improve the completeness and
transparency of reporting of interventions in  controlled trials of
acupuncture, in order that such trials may  be more accurately inter-
preted and readily replicated. STRICTA comprised a  checklist that
expanded the generic content of Item 5 of the CONSORT statement
[10,11],  which relates to the reporting of the intervention.
A survey of authors of clinical trials and systematic reviews was
subsequently conducted to determine the usefulness of STRICTA in
http://dx.doi.org/10.1016/j.arthe.2016.03.001
2211-7660/© 2016 Published by Elsevier GmbH. This is an open access article under the CC  BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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helping them write their reports [12].  In addition, a survey of 90
acupuncture trials was undertaken to assess whether use of the
STRICTA checklist was associated with improved reporting over
time [13].  The results of these initiatives led  to  conclusions that
most STRICTA items were found to be necessary and easy to use,
though some were seen as poorly reported, ambiguous or possibly
redundant, and a  number of suggestions were made for additional
items. A  revision of STRICTA was therefore proposed.
Meanwhile, extensions to CONSORT have been developed to
cover the reporting of non-pharmacological treatments [14,15] and
pragmatic trials [16]. Since there are acupuncture specific aspects
to reporting not covered by  these extensions, it was  decided that
STRICTA should be revised in a  manner congruent with CONSORT
and its extensions for non-pharmacological treatments and prag-
matic trials.
The combination of these developments led to an agreement
between the CONSORT Group and the STRICTA Group, in  collabora-
tion with the Chinese Cochrane Centre and the Chinese Centre for
Evidence-based Medicine, to  revise STRICTA as a  formal extension
to CONSORT. The revision processes have been described in more
detail elsewhere [17].  This paper describes the outcome in  terms of
a new checklist, updated explanations, and published examples of
good reporting.
2. Methods
In the summer of 2008, a  group of 47 experts from the orig-
inal STRICTA Group, the CONSORT Group, the World Federation
of Acupuncture and Moxibustion Societies, the Acupuncture Trial-
ists’ Collaboration [18],  the Society for Acupuncture Research [19],
and clinical trial authors were surveyed [12].  The experts were
from 15 countries, 41 had academic positions, 31 were acupunc-
turists, 18 were involved with journals, such as board members, 15
were physicians, and 11 had been involved previously in  develop-
ing reporting guidelines. These experts were consulted in regard
to a draft of revised STRICTA items that  had evolved from previous
research [12,13].  Feedback was collated and forwarded (with per-
mission) to those invited to a  consensus development workshop,
the next phase of the revision process.
Twenty-one individuals attended a workshop in  Freiburg,
Germany, in October 2008. The attendees included experts in
epidemiology, trial methodology, statistics, and medical journal
editing. Just over half the participants were acupuncturists from
a variety of backgrounds, including physician and non-physician.
All attendees received collated feedback from the 47 experts, along
with a draft revised STRICTA checklist for consideration.
The workshop comprised presentations about the history
of STRICTA, CONSORT, and the then new CONSORT non-
pharmacological treatments extension [14,15].  The results of two
investigations into the utility and acceptability of STRICTA [12,13],
and the subsequent consultation with the 47 experts, were also
presented. A general discussion and agreement on generic issues
relating to STRICTA were followed by  a  discussion of each nomi-
nated checklist item. The aim was to agree, where possible, on the
content of the updated draft checklist as well as to develop a revised
set of explanations for each included item.
Subsequent to the workshop, a small writing group edited drafts
of the revised STRICTA checklist, identifying for each item one or
more exemplars of good reporting, and developed text explaining
the rationale and discussing relevant evidence. Taking into account
further feedback from those attending the Freiburg workshop, the
writing group finalised the STRICTA checklist, the explanations and
the examples of good reporting.
3. Results
There was agreement that STRICTA should continue to function
as a  stand-alone guideline for reporting acupuncture studies, and
be an official extension of CONSORT for reporting randomized con-
trolled trials. There was  also consensus on a minor change of name,
in that the word “controlled” in STRICTA should be replaced by
“clinical”, to indicate that it was  applicable for reporting a  broad
range of clinical evaluation designs, including uncontrolled out-
come studies and case reports. The group agreed that the rationale
behind reporting should be to  provide the information needed to
allow replication of a study, reduce ambiguity and enhance trans-
parency. The group recognised that acupuncture trials inevitably
differ in  the degree of individualisation of care that is permitted,
and agreed that the reporting guideline should acknowledge this
and be applicable across the whole range of designs. The group also
suggested that  the revised STRICTA statement, when published,
should be presented as embedded within the two-group parallel
trial CONSORT checklist [10] and its non-pharmacological treat-
ment extension checklist [14].
The revised STRICTA checklist comprises six items broken out
into seventeen sub-items (Table 1). Table 2 presents how the
revised STRICTA checklist fits within the CONSORT checklist [10]
and its extension for non-pharmacological treatments [14]. Below
we provide the checklist text for each of the six items and their
sub-items, as well as explanations on the need for their adequate
reporting and examples of good reporting from the published lit-
erature.
3.1. STRICTA item 1: acupuncture rationale
3.2. Item 1a
Style of acupuncture (e.g. Traditional Chinese Medicine,
Japanese, Korean, Western medical, Five Element, ear  acupuncture,
etc.).
3.2.1. Explanation
Acupuncture has a  long history in many cultures and is charac-
terised by a  broad diversity of styles and approaches in both East
Asia and the West [20].  In order for the readers to  contextualize
the trial within the range of current clinical practices, researchers
should state the overall style or approach on which they have  based
the treatments. If the researcher believes the treatment approach
is  completely novel, then this should be clearly stated.
3.2.1.1. Examples2.
(i) We based the acupuncture point selections on Traditional Chi-
nese Medicine meridian theory to  treat knee joint pain, known
as the “Bi” syndrome [21].
(ii) Participants were randomized to two styles of acupuncture:
Japanese style (Kiiko-Matsumoto’s Form) and Traditional Chi-
nese Medicine style [22].
(iii) Four out of five of the acupuncturists primarily practised
the Five Element style with a  diagnostic focus on individual
‘Causative Factors’, (ref) and one used the Traditional Chi-
nese Medicine (TCM) style with diagnosis primarily based on
syndrome patterns (ref). Both styles are rooted in traditional
acupuncture theory, and they are  the most common tradi-
2 Note: In the Examples that follow, the embedded terms (ref) and (refs) refer to
sources that are reported in the original published studies, but the details of these
sources are not provided in this article for reasons of brevity.
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Table 1
STRICTA 2010 checklist of information to include when reporting interventions in a  clinical trial of acupuncture.
Item Detail
1. Acupuncture rationale 1a) Style of acupuncture (e.g. Traditional Chinese Medicine, Japanese, Korean, Western medical, Five Element, ear
acupuncture, etc.)
1b)  Reasoning for treatment provided, based on  historical context, literature sources, and/or consensus methods, with
references where appropriate
1c)  Extent to  which treatment was varied
2.  Details of needling 2a) Number of needle insertions per  subject per session (mean and range where relevant)
2b)  Names (or location if no standard name) of points used (uni/bilateral)
2c)  Depth of insertion, based on a specified unit of measurement, or on a particular tissue level
2d)  Response sought (e.g. de qi or muscle twitch response)
2e) Needle stimulation (e.g. manual, electrical)
2f)  Needle retention time
2g) Needle type (diameter, length, and manufacturer or material)
3. Treatment regimen 3a) Number of treatment sessions
3b)  Frequency and duration of treatment sessions
4. Other components of treatment 4a) Details of other interventions administered to  the acupuncture group (e.g. moxibustion, cupping, herbs, exercises,
lifestyle advice)
4b) Setting and context of treatment, including instructions to  practitioners, and information and explanations to
patients
5.  Practitioner background 5) Description of participating acupuncturists (qualification or professional affiliation, years in acupuncture practice,
other  relevant experience)
6.  Control or comparator interventions 6a) Rationale for the control or comparator in the context of the research question, with sources that justify this choice
6b) Precise description of the control or comparator. If sham acupuncture or any other type of acupuncture-like
control is used, provide details as for Items 1–3 above.
Note: This checklist, which should be read in conjunction with the explanations of the STRICTA items provided in  the main text, is  designed to  replace CONSORT 2010’s item
5  when reporting an  acupuncture trial.
tional approaches used by professional acupuncturists in the
UK today (ref) [23].
(iv) Each patient was treated with non-local needle acupuncture
(according to  the theory of channels of Traditional Chinese
Medicine) at distant points, and dry needling of local myofas-
cial trigger points [24].
3.3. Item 1b
Reasoning for treatment provided, based on historical con-
text, literature sources, and/or consensus methods, with references
where appropriate.
3.3.1. Explanation
The author(s) should provide the reasoning for the chosen
treatment, including rationale for diagnosis, point selection and
treatment procedures. The “rules” that were used in providing
treatments should be described. When treatments were selected
that have roots in traditional practice, it is recommended that the
historical and cultural context be supplied. This is  relevant for inter-
ventions within styles such as “Traditional Chinese Medicine” or
“TCM”, where the broad diversity of approaches requires careful
identification of where and when the treatment parameters were
developed. Where consensus methods, expert clinical panels, prac-
titioner surveys or some combination of sources have been used to
define the treatment protocol, it is  recommended that full details of
the methodology be  given. Literature and other sources should be
provided where relevant, in order that others can replicate the trial
by consulting these source(s) and/or developmental methods on
which treatment was based. Authors are encouraged to reference
published works that  are  easily obtainable, such as a  book or jour-
nal article. If the reference is  a thesis, non-published work, written
material only available in a different language from the journal arti-
cle, or a verbal communication, authors are encouraged to present
or summarise the information in an appendix or make it other-
wise generally available (e.g. on a website). For fully individualised
trials where the goal is  to have representative practitioners who
are encouraged to  practice as they normally do, it is appropriate to
specify the selection process for the practitioners, providing details
of criteria for their inclusion. It is  important to note that where
details of the intended intervention are defined in advance, it is
possible that what was  actually administered may have differed. In
such cases, precise details of the treatments that were provided are
also necessary.
3.3.1.1. Examples.
(i) This study employed a  style of Japanese acupuncture devel-
oped by Shima and Chace (ref) and Manaka (ref), and follows
the Japanese acupuncture training curriculum at the New
England School of Acupuncture. In comparison to typical
traditional Chinese medicine (TCM) acupuncture, Japanese
acupuncture uses smaller needles and inserts needles less
deeply and with less manipulation (ref). For  these reasons, we
believed Japanese acupuncture would be less invasive than
TCM, and thus better received by our  adolescent population.
Japanese acupuncture has been shown to  be effective in treat-
ing certain pain conditions (ref). The specific acupuncture
protocols employed in this study are briefly described below
and discussed in greater detail in  a companion paper (ref) [25].
(ii) We based point selection on individualised Western acupunc-
ture techniques by using a  list of points previously reported as
being effective in  neck pain (refs) and by reaching a consen-
sus according to our own  clinical and teaching practice (ref).
The specific points for each individual were defined at each
treatment session, depending on the patient’s pain distribu-
tion and palpation of the neck and thorax to determine ah-shi
points, or local tender points, for acupuncture. At least one dis-
tal point was  used. Point location and depth of insertion were
as described in traditional texts (ref) [26].
(iii) We developed the treatment strategies for acupuncture and
minimal acupuncture in a  consensus process with three
acupuncture specialists (names provided) representing two
major German societies for medical acupuncture: the German
Medical Acupuncture Association (Deutsche Ärztegesellschaft
für Akupunktur, DÄGfA) and the International Society for Chi-
nese Medicine (Societas Medicinae Sinensis, SMS). The first
step involved three specialists (names provided) and the study
team developing a  proposal, which was followed by  a discus-
sion including more than 30 acupuncture experts from both
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Table  2
CONSORT 2010 checklist with the Non-pharmacological Trials Extension to CONSORT (with STRICTA 2010 extending CONSORT Item 5 for acupuncture trials).
Section/Topic Item # CONSORT 2010 Statementa:  Checklist item [10].  Describe: Additional items from the Non-pharmacological Trials
Extension to CONSORT [14].  Add:
TITLE AND
ABSTRACT
1.a Identification as a randomized trial in the title In the abstract, description of the experimental treatment,
comparator, care providers, centers and blinding status.
1.b  Structured summary of trial design, methods, results, and
conclusions; for specific guidance see CONSORT for
Abstracts [58,59]
INTRODUCTION
Background and
objectives
2.a Scientific background and explanation of rationale
2.b Specific objectives or hypotheses
METHODS
Trial design 3.a Description of trial design (e.g., parallel, factorial)
including allocation ratio
3.b  Important changes to  methods after trial commencement
(e.g. eligibility criteria), with reasons
Participants 4.a Eligibility criteria for participants When applicable, eligibility criteria for centers and those
performing the interventions.
4.b  Settings and locations where the data were collected
Interventions 5 The interventions for each group with sufficient details to
allow replication, including how and when they were
actually administered
Precise details of both the experimental treatment and
comparator - see Table 1 for details
Outcomes 6.a Completely defined pre-specified primary and secondary
outcome measures, including how and when they were
assessed
6.b Any changes to trial outcomes after the trial commenced
with reasons
Sample  size 7.a How sample size was determined When applicable, details of whether and how the
clustering by care providers or centers was addressed.
7.b When applicable, explanation of any interim analyses and
stopping guidelines
Randomization
Sequence
generation
8.a  Method used to generate the random allocation sequence When applicable, how care providers were allocated to
each  trial group.
8.b Type of randomization; details of any restriction (e.g.,
blocking and block size)
Allocation
concealment
9 Mechanism used to implement the random allocation
sequence (e.g., sequentially numbered containers),
describing any steps taken to  conceal the sequence until
interventions were assigned
Implementation 10 Who generated the random allocation sequence, who
enrolled participants, and who assigned participants to
interventions
Blinding 11.a If done, who was blinded after assignment to interventions
(e.g. participants, care providers, those assessing
outcomes) and how
Whether or not those administering co-interventions were
blinded to group assignment. If blinded, method of
blinding and description of the similarity of interventions.
11.b If relevant, description of the similarity of interventions
Statistical methods 12.a Statistical methods used to compare groups for primary
and secondary outcomes
When applicable, details of whether and how the
clustering by care providers or centers was addressed.
12.b Methods for additional analyses, such as subgroup
analyses and adjusted analyses
RESULTS
Participant flow (A
diagram is strongly
recommended)
13.a For each group, the numbers of participants who  were
randomly assigned, received intended treatment, and were
analyzed for the primary outcome
The number of care providers or centers performing the
intervention in each group and the number of patients
treated by each care provider or in each center.
13.b For each group, losses and exclusions after randomization,
together with reasons
Implementation of
intervention
Details of the  experimental treatment and comparator as
they were implemented.
Recruitment 14.a Dates defining the periods of recruitment and follow-up
14.b Why  the trial ended or was stopped
Baseline data 15 A Table showing baseline demographic and clinical
characteristics for each group
When applicable, a  description of care  providers (case
volume, qualification, expertise, etc.) and centers (volume)
in  each group.
Numbers analyzed 16 For each group, number of participants (denominator)
included in each analysis and whether the analysis was by
original assigned groups
Outcomes and
estimation
17.a For each primary and secondary outcome, results for each
group, and the estimated effect size and its precision (e.g.,
95% confidence interval)
17.b For binary outcomes, presentation of both absolute and
relative effect sizes is recommended
Ancillary analyses 18 Results of any other analyses performed, including
subgroup analyses and adjusted analyses, distinguishing
pre-specified from exploratory
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Table 2 (Continued)
Section/Topic Item #  CONSORT 2010 Statementa:  Checklist item [10].  Describe: Additional items from the Non-pharmacological Trials
Extension to  CONSORT [14]. Add:
Harms 19 All  important harms or unintended effects in each group;
for  specific guidance see CONSORT for Harms [60]
DISCUSSION
Limitations 20 Trial limitations, addressing sources of potential bias,
imprecision, and,  if relevant, multiplicity of analyses
Generalizability 21 Generalizability (external validity, applicability) of the trial
findings
Generalizability (external validity) of the trial findings
according to  the intervention, comparators, patients and
care providers and centers involved in the trial.
Interpretation 22 Interpretation consistent with results, balancing benefits
and  harms, and considering other relevant evidence
In addition, take into account the  choice of the  comparator,
lack of or partial blinding, unequal expertise of care
providers or centers in each group.
OTHER
INFORMATION
Registration 23 Registration number and name of trial registry
Protocol 24 Where the full trial protocol can be accessed, if  available
Funding 25 Sources of funding and other support (e.g., supply of
drugs);  role  of funders
a We  strongly recommend reading this Statement in conjunction with the CONSORT 2010 explanation and elaboration [11] for important clarifications on  all the items.
If  relevant, we  also recommend reading CONSORT extensions for cluster randomized trials [61], noninferiority and equivalence trials [62],  herbal interventions [63], and
pragmatic trials [16]. Moreover, additional extensions are  forthcoming. For those and also for up-to-date references relevant to this checklist, see http://www.consort-
statement.org.
acupuncture societies. The final intervention strategies were
defined by  the above mentioned three specialists together with
the study team and subsequently were communicated to the
external advisors [27].
3.4. Item 1c
Extent to which treatment was varied.
3.4.1. Explanation
The extent to which the treatment was individualised, both
between patients and between practitioners, should be described.
Trial protocols choose one of three broad levels of individualisation,
ranging from none at all (all patients receiving the same treatment
at all sessions), through partially individualised treatments (e.g. use
of a fixed set of points to  be combined with a  set of points to  be
used flexibly), to fully individualised treatment protocols within
which each patient receives a  unique and evolving diagnosis and
treatment. Additionally, the practitioners may  have to  apply a stan-
dardised theoretical framework, or may  be allowed to apply their
own. Many styles of acupuncture, whether based on traditional
theories or Westernized concepts such as trigger points, are indi-
vidualised in routine practice. Trials that are more pragmatic [28]
in their aim, and designed to replicate routine settings and patient
groups, have more of an emphasis on fully individualised treat-
ment. In such cases standardisation may  consist of a protocol that
instructs practitioners to  provide treatments as they normally do.
Trials that are more explanatory (mechanistic) in their aim tend to
need a tighter definition of specific components in  order to min-
imise variation across treatments.
3.4.1.1. Examples.
(i) Each patient received individualised acupuncture treatments
that focused on specific needs and symptoms that the indi-
vidual was experiencing. The rationale for this intervention
was to test acupuncture as it is  typically performed in  practice.
Point selection was based on the general principles of acupunc-
ture and Traditional Chinese Medicine (ref). The treatment was
modified over the course of the study to  accommodate the indi-
vidual’s changing pattern of pain, sleep, or other health issues
[29]
(ii) The verum points consisted of obligatory points and additional
points individually chosen by the physicians on the basis of  tra-
ditional Chinese medicine diagnosis for syndromes (including
tongue diagnosis), acupuncture channels related to the indi-
vidual headache area, and Ah Shi points (locus dolendi points)
[30].
(iii) The acupuncture protocol was based on the concept of ade-
quacy of treatment, (ref) survey results, (ref) a  consensus
workshop, and recommendations from traditional Chinese
protocols. We did not allow moxibustion, cupping, herbs, or
electroacupuncture. For each individualised treatment session
between six and 10 acupuncture points from 16  commonly
used local and distal points were selected. Local points were
Sp 9,  Sp 10, St 34, St 35, St 36, Xiyan, Gb 34, and trigger points.
Distal points were LI  4, TH5, Sp 6, Liv 3, St 44, Ki 3, BI 60,  and
Gb 41 [31].
3.5. STRICTA item 2: details of needling
3.6. Item 2a
Number of needle insertions per subject per session (mean and
range where relevant).
3.6.1. Explanation
It is  recommended that the reporting of this item should include
a  total of needle insertions per subject per session. This item is rele-
vant to  all designs of randomized controlled trials, from pragmatic
to  explanatory. For more explanatory designs where a formula of
points is prescribed, the number of needle insertions should be
reported as a  simple total. For more pragmatic designs, with indi-
vidualised treatments, the mean and range should be reported.
Clearly, full details of individualised treatment cannot be reported
in  every section of Item 2 below. However, each item  should be
considered and as much information given as possible.
3.6.1.1. Examples.
(i) The protocol allowed for up to 10 treatments per patient,
the precise number being agreed between patient and prac-
titioner. A total of 1269 treatments were provided, an average
of 8.6  treatments per patient (range 1–10) and 9.6 needles
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per treatment (range 6–12). See  (table) for variations between
practitioners [32].
(ii) Disposable stainless steel needles (0.2 × 50 mm,  Seirin) were
inserted into the skin over the trigger point to a  depth of
10–30 mm,  appropriate to  the muscle targeted, attempting
to  elicit a local muscle response using the “sparrow pecking”
technique. After the local twitch response was  elicited or a  rea-
sonable attempt made, the needle was retained for a  further
ten minutes. The mean number of insertions was 3.3 [33].
(iii) In the real acupuncture group, the acupuncture points Hegu
(LI 4), Jiache (St 6), Xiaguan (St 7) and Yifeng (SJ 17) were used
unilaterally on the tooth extraction side [34].
3.7. Item 2b
Names (or location if no standard name) of points used
(uni/bilateral).
3.7.1. Explanation
The point descriptions in  the seminal classic texts, such as the
Huangdi Neijing (Inner Canon of the Yellow Emperor) are rare
and vague. The depiction of acupuncture points in  relation to pre-
cise anatomical structures dates back only 100 years. Since the
mid  1950s a process of standardisation has been taking place,
and the acupuncture point descriptions based on anatomical loca-
tions and proportional cun measurement systems have served as
a blueprint for many Western translations. It  should be noted that
these locations have not been universally adopted. Given this his-
torical context, it remains important to know which acupuncture
points have been used in  clinical trials, with as accurate descrip-
tions as possible of the location of these points, and where relevant
the method used to  identify the points.
The specific point locations used in  treatments where standard-
ised should be described in  terms of an accepted nomenclature (e.g.
GB21) [35] or in terms of anatomical location where there is no
accepted name. Whether the needles are inserted unilaterally or
bilaterally should be stated. For protocols with partially individu-
alised prescriptions, list  any prescribed essential or optional points,
and describe (in Section 3) both the points used at every visit, and
all the points used on an ad hoc basis. If the list  is  extensive, the
most commonly used points (with percentages) should be reported.
Where protocols specify using fully individualised point prescrip-
tions, authors should consider the best way to report the points
used, for example by  listing all points across all subjects, or by
identifying the most commonly used points if  the list  is extensive.
3.7.1.1. Examples.
(i) We  based the acupuncture point selections on Traditional
Chinese Medicine meridian theory to treat knee joint pain,
known as the “Bi” syndrome. These points consisted of 5 local
points (Yanglinquan [gall bladder meridian point 34], Yinlin-
quan [spleen meridian point 9], Zhusanli [stomach meridian
point 36], Dubi [stomach meridian point 35], and extra point
Xiyan) and 4 distal points (Kunlun [urinary– bladder, meridian
point 60], Xuanzhong [gall bladder meridian point 39], Sany-
injiao [spleen meridian point 6], and Taixi [kidney meridian
point 3]) on meridians that  traverse the area of pain (refs). The
same points were treated for each affected leg. If both knees
were affected, 9 needles were inserted in  each leg [21].
(ii) The VA (verum acupuncture) group received acupuncture with
a 0.25 × 40-mm stainless steel needle (Asia Med, Munich,
Germany) at LI4, which is situated between the first two
metacarpal bones on the dorsal side of both hands at the top
of the muscle belly (figure provided) [36].
(iii)  The most frequently treated local points were Bl  23, Bl  25, Gb
30, DU 4, Bl  26, and the extra point Huatuojiaji (table provided)
..  . ..  The most frequently treated distant points were Bl 40, Kid
3, Gb 34, Bl 60,  SI 3, and DU 20. In most cases, 8–12 local points
and 4–6 distant points were used. Physicians used additional
acupuncture points in 565 of the treatment sessions. The most
frequently used additional local points were Li 4,  St 40, Bl  17,
Sp 6, and St 36 [27].
3.8. Item 2c
Depth of insertion, based on a  specified unit of measurement, or
on a particular tissue level.
3.8.1. Explanation
The depth of insertion should be expressed using the Chinese
measurement of the cun; in  terms of anatomical depth, for example,
of subcutaneous tissue, fascia, muscle or periosteum; or in  mil-
limetres. For some trials, the protocol might specify the angle and
direction of insertion along with depth of insertion, in  which case
these should also be reported.
3.8.1.1. Examples.
(i) All  needle placements were performed by an experienced
acupuncturist at a  premarked depth of 4 mm from the tip of
the needle [37].
(ii) The depth of needle insertion varied with thickness of  the skin
and subcutaneous fatty tissues at the site of the acupuncture
points; it was usually 1–1.5 cm [38].
(iii) Shallow and light needling stimulation (1–2 mm)  using fine
needles (0.18–0.16 mm)  inserted with the aid of insertion
tubes was  emphasized. Points were needled at a 10◦–20◦ angle
with a  2-hand needling technique, generally in the direction of
the flow of the channel [39].
3.9. Item 2d
Responses sought (e.g., de qi or muscle twitch response).
3.9.1. Explanation
If the study protocol requires that specific responses to needling
be elicited, for example the de  qi sensation in  traditional Chinese
acupuncture, the muscle twitch in trigger point treatment or  mus-
cle contraction in electro-acupuncture, these elicited responses
should be reported. Where relevant, the authors should differen-
tiate between the responses required in  the protocol and those
actually obtained (which should be reported in Section 3).
3.9.1.1. Examples.
(i) The TRP (trigger point) group received treatment at trigger
points. The correct application of the technique requires expe-
rience in  palpation and localisation of taut muscle bands and
myofascial trigger points. Precise needling of myofascial trig-
ger points provokes a brief contraction of the muscle fibres. This
local twitch response must be elicited for successful therapy but
it may  be painful and post treatment soreness is  frequent [33].
(ii) In contrast with TCM style acupuncture, we did not employ
vigorous manipulation in  order to elicit a strong de qi sensation
(defined as a  feeling of heaviness around the acupuncture point)
(ref). Practitioners focused instead on feeling the response to
stimulation as an “echo” sensation experienced on the receiv-
ing hand, while the active hand performed the actual needling.
Attention was  placed on reactivity or change in diagnostic
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areas, especially the pulse and abdomen. By carefully assess-
ing changes in  palpatory findings, the treatment was adjusted
continuously based on the patient’s response. Before needling,
the “live” points were identified by palpation, that is, subtle
changes at the skin level, or upon touch or  pressure, for that
particular patient [39].
3.10. Item 2e
Needle stimulation (e.g. manual or electrical).
3.10.1. Explanation
Needle stimulation techniques, where used, should be clearly
described for all points. For manual stimulation, such techniques
include lifting, thrusting or  rotating the needle to manipulate the
de qi sensation. For electrical stimulation, the current, amplitude
and frequency settings should be recorded.
3.10.1.1. Examples.
(i) This mode of (manual) stimulation was provided via the
acupuncture needles, which were placed in the premarked
depth at the marked sites. The needle was rotated by an expe-
rienced acupuncturist with the index finger and thumb in  an
alternating clockwise and counterclockwise fashion at the rate
of three to five rotations per second [37].
(ii) Electrical stimulation was given to the anterior part of the
knee for 10 min  and then 10 min  for the posterior part using
a battery-operated, four-channel, ‘AS Super 4′ Electrostimula-
tor (RDG Medical, Surrey UK) which generated low frequency,
square-wave (2–10 Hz) pulses of 1 millisecond duration for
10  min  (ref). In both groups, the apparatus was  attached to nee-
dles at the two Xiyan points, SP9 and GB34, and BL40 and BL57.
Electrical stimulation was delivered at 6 Hz at a  constant cur-
rent. Voltage was set at a  level just above the pain threshold
[38].
3.11. Item 2f
Needle retention time.
3.11.1. Explanation
Needle retention times should be reported as either a standard
or a mean and range. Authors should make it clear that they are
reporting the time elapsed between the insertion and removal of
needles (retention time) and distinguish it from treatment time,
which may  include other procedures such as history taking, dis-
cussion and preparation for treatment.
3.11.1.1. Examples.
(i) Each participant was treated bilaterally and had a  total of six
needles inserted for the duration of the treatment. A draining
technique was used and the needles were left for a  period of
30 min. The practitioner returned to check on the participant
at regular intervals during the intervention [40].
(ii) Needles were withdrawn immediately for tonification, and
retained for up  to 20 min  for the evens technique [23].
(iii) Therapists allow 25 (min)–35 (max) minutes between inser-
tion of the last needle and cessation of treatment and during
that time they are to revisit the needles as appropriate [41].
(iv) The patients in group A were dry needled for a  few seconds.
For trigger point inactivation by dry  needling. . . it is  especially
important not  to apply too strong a  stimulus because this may
produce a  flare-up of the patient’s symptoms [42].
3.12. Item 2g
Needle type (diameter, length, and manufacturer or material).
3.12.1. Explanation
Details should be given of the types of needles used, including
the diameter and length as well as the manufacturer and/or the
material. This information is  of importance since the effect of dif-
ferent metals or  needle sizes on the body is not known. For trials
using a variety of different types of needles, the ranges of  diameters
and lengths as well as types of material should be reported.
3.12.1.1. Examples.
(i) Seirin 36 gauge 2.5 in. long unused sterile L-type needles were
used for the study [37].
(ii) The VA (verum acupuncture) group received acupuncture with
a  0.25 × 40-mm stainless steel needle (Asia Med, Munich,
Germany) at LI4 [36].
4.  STRICTA item 3: treatment regimen
4.1. Item 3a
Number of treatment sessions.
4.1.1. Explanation
The planned number of sessions and frequency of  treatment
should be clearly documented. The actual number of treatments
received by participants should be reported in Section 3.  If there
is variation between patients, then the mean and range should be
reported.
4.1.1.1. Examples.
(i) The true acupuncture (experimental) group underwent 26
weeks of gradually tapering treatment according to the follow-
ing schedule: 8 weeks of 2 treatments per week followed by 2
weeks of 1 treatment per week, 4 weeks of 1 treatment every
other week, and 12 weeks of 1 treatment per month [21].
(ii) In all groups, participants were asked to attend treatment
sessions twice weekly for 12 weeks (24 treatments). We con-
sidered participants who  attended 80% or more (≥19 of  24) of
acupuncture sessions to have completed a  full course of  treat-
ment [43].
4.2. Item 3b
Frequency and duration of treatment sessions.
4.2.1. Explanation
The frequency and duration of sessions should be documented,
with mean and range to  be  reported where there is variation across
patients. Any variation in  frequency of treatment (for example if
subjects are to be treated twice weekly in the first two  weeks then
once a week for the next six weeks) should be clearly reported.
4.2.1.1. Examples.
(i) Acupuncture was  administered a  maximum of eight times, twice
during each of the first three weeks and once during each of the
following two  weeks, for 30 min  at each session. One month after
this series of treatments had been completed and evaluated, the
patients were offered a  maximum of two follow up treatments
of the same kind, one week apart [44].
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5. STRICTA item 4: other components of treatment
5.1. Item 4a
Details of other interventions administered to the acupuncture
group (e.g. moxibustion, cupping, herbs, exercises, lifestyle advice).
5.1.1. Explanation
Additional components of treatment refer to the auxiliary tech-
niques, prescribed self-treatment and lifestyle advice provided by
the practitioner. All  additional components, whether carried out
by the practitioner or  patient and whether integral or adjunc-
tive to the acupuncture needling, should be described clearly. For
acupuncture related interventions, such as moxibustion or  cup-
ping, detail should be provided equivalent to that recommended
for acupuncture needling. If the protocol specifies the options of
prescribed self-help treatments such as qigong or muscle stretch-
ing exercises, and/or lifestyle advice such as dietary changes based
on acupuncture-related diagnostic criteria, then these too must
be reported. The frequency with which the advice was given,
and participants’ compliance with this advice, should be reported.
“Other components of treatment” should be distinguished from
“co-interventions”, that is interventions that are  provided addition-
ally to both groups, which should be fully reported as described in
STRICTA Item (6b) below.
5.1.1.1. Examples.
(i) In addition to needling, moxibustion or thermal stimulation
of the acupoints was used forming very fine wool of mug-
wort (Artemisa vulgaris) into minute, thread-size punks (okyu¯)
and placing them on a  thin layer of an herbal cream (shiunko).
The moxa was lit with an incense stick and the process was
repeated several times until warmth was felt by the patient
[39].
(ii) Following application of the studs, patients were instructed to
apply pressure to the stud by making small circular movements
with the fingers of the opposite hand, 2–3 cycles per second for
1–2 min  per point. As is typical for self-administered acupres-
sure, patients were encouraged to apply acupressure this way
on waking, in  the early afternoon and during any exacerba-
tion of symptoms. Initial instruction was provided verbally, at
which time patients were asked to confirm their understand-
ing by demonstrating the procedure. Patients also were given
easy-to-read written materials describing the acupressure pro-
cedure [45].
(iii) Chinese herbal medicine was to be taken three times per
day over a  period of 6 weeks and parallel to acupuncture
treatment.  . . All herbs used in the present study were imported
from China by  a single TCM herbal medicine import company
(Sinores, Lueneberg, Germany).  . . All herbs were prepared in
dried, minced pieces and then sealed in generic paper sachets
by a pharmacist in order to render the herbal formulation non-
identifiable for patients. . . In  addition to  the basic formula,
every patient received a  second additional formula tailored to
his or her individual TCM diagnosis [46].
5.2. Item 4b
Setting and context of treatment, including instructions to  prac-
titioners and information and explanations to patients.
5.2.1. Explanation
The setting and context of treatment can also provide important
additional components to treatment [47].  Context includes instruc-
tions to practitioners that might modify their normal practice, for
example, prescribing or  proscribing explanations to patients about
their diagnosis. For patients, the context includes the informa-
tion they have been given about the trial that might be expected
to modify outcomes. Therefore, the information that the patient
receives regarding the treatment and control intervention should
be reported, including any relevant wording on consent forms and
information leaflets designed to influence beliefs or expectations.
For example, describing a sham acupuncture control as “a type of
acupuncture” may  have a  different effect on outcome than say-
ing it is “not acupuncture, but will involve a  similar experience to
acupuncture.”
5.2.1.1. Examples.
(i) The first acupuncturist was the ‘diagnosing acupuncturist’ (DA),
whom the patient saw for the initial consultation, and before
and after each treatment. A full case history was taken by  the
DA, together with tongue and pulse examination, to arrive at an
individual diagnosis in accordance with the principles of TCM,
with an additional lesser emphasis on Five Element Acupunc-
ture (refs). Although all patients in  the study had IBS, this
corresponded to a  wide range of TCM patterns, making individ-
ual diagnosis essential. Dietary and lifestyle advice (important
in treatment according to TCM principles) was given to all
patients by the DA, who then selected acupuncture points. The
second “treating acupuncturist” (TA) opened the randomiza-
tion envelope, and for the duration of the study remained the
only individual aware of treatment allocation. The TA carried
out the treatment −  either according to  instructions issued by
the DA or using sham points, depending on the randomization
[48].
(ii) Patients were informed about acupuncture and minimal
acupuncture in the study as follows: “In this study, different
types of acupuncture will be compared. One type is similar to
the acupuncture treatment used in China. The other type does
not follow these principles, but has also been associated with
positive outcomes in clinical studies” [27].
6. STRICTA item 5: practitioner background
6.1. Item 5
Description of participating acupuncturists (qualification or
professional affiliation, years in acupuncture practice, other rele-
vant experience).
6.1.1. Explanation
Characteristics of the acupuncturists providing treatment
should be reported, including qualification or  affiliation, years in
acupuncture practice, as well as any other experience that may  be
relevant to the trial. Relevant differences (if any) in  the qualifica-
tion, training and experience of the participating acupuncturists
should be highlighted. The recent survey of authors of acupuncture
trials and reviews reinforced the need for these characteristics to be
reported well [12],  especially since the actual level of reporting has
historically been poor [13].  In trials where different acupuncturists
provide treatment to  different treatment arms, the background of
both groups should be reported. The eligibility criteria for acupunc-
turists should be  explained, as these will influence generalisability
of the trial results. Where there are  known to be  potential variations
between practitioners, selecting a random sample of practitioners
will reduce expertise bias and help improve the applicability of the
results [49].
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6.1.1.1. Examples.
(i) Physicians had a median of 350 h (range 140–2508 h) of
acupuncture training before participating in the trial; 33 (73%)
had the B-Diploma. Seventeen (17; 38%) trial  physicians taught
acupuncture in accredited postgraduate courses. The physi-
cians had used acupuncture in  their practices for an average of
11 years (median 10, range 0–25) and had treated 346 patients
(range 22–1200) with acupuncture in  the year before the trial.
Forty-one physicians (92%) indicated that they frequently or
always make a  Chinese syndrome diagnosis before starting
treatment [27].
(ii) Eight US-trained and licensed acupuncturists with a  median
of 10 years of experience (range 4–18 years) provided study
treatments in their private offices. One investigator trained the
acupuncturists in the study procedures to increase their com-
fort with delivering all 4 treatments and monitored compliance
with the protocol throughout the study [43].
(iii) Of the 11 midwives participating in the study, six had been
taught acupuncture for midwives at the Norwegian School of
Acupuncture/NFKA. These six gave real and false acupuncture,
whereas the others, who had been trained in  acupuncture by
the six, were allowed only to give false acupuncture [50].
7.  STRICTA item 6: control and comparator interventions
7.1. Item 6a
Rationale for the control or  comparator in the context of the
research question, with sources that justify the choice(s).
7.1.1. Explanation
The rationale for choice of control or comparator should be
presented and justified in relation to the research question and
the methodology. In  studies in which a  group receiving acupunc-
ture is compared with another group, the control or comparator
can be sham acupuncture, usual care, an active treatment, a  wait-
ing list or no treatment. Whereas ‘control’ is sometimes used
for a group that receives no intervention, the term ‘compara-
tor’ may  be more appropriate for an active intervention, such as
physiotherapy, for which the intended action of the compara-
tor is expected to  be therapeutic. If using an acupuncture-like
control in a participant-blinded trial then one of the following
terms: active acupuncture control; penetrating needle control; or
non-penetrating sham needling control might be helpful descrip-
tors. Control procedures involving invasive or  non-invasive sham
needling techniques may  be therapeutically active, evoking neuro-
physiological and/or localised immune and circulatory responses.
The extent that sham acupuncture needling, whether penetrating
or not, might elicit acupuncture-specific physiological mechanisms
is  not known, and is in part a  consequence of our lack of knowledge
of the mechanism(s) of true acupuncture. There are also variations
in assumptions about the precision required for point location, as
for some clinicians and investigators, acupuncture points are con-
sidered as areas of reactivity rather than points of action. Such
assumptions have a  bearing on the integrity of the sham as an
appropriate control. Some non-needling control procedures can be
assumed to be physiologically inert, such as an inactivated tran-
scutaneous electrical nerve stimulation (TENS) machine; however,
these procedures may  not have the same total psychophysiological
credibility as acupuncture, thereby compromising the interpreta-
tion of the results. Sources that led to the choice of control, such
as literature or  expert opinion, should also be reported and refer-
enced. The author should reference prior work that supports the
use of the selected comparator, such as from the conclusion of a
systematic review or from another randomized controlled trial.
7.1.1.1. Examples.
(i) ‘Sham’ acupuncture points were chosen from three different
areas  on the body (the anterior thigh distally, the posterior
thigh, and the lateral aspect of the lower back), which do not
correspond to recognised acupuncture points and are  deemed
to have no therapeutic value [48].
(ii) International guidelines suggest that the best package of care
for this patient group is  one that includes patient education,
advice and exercise (ref). . . ..  Randomised clinical trials con-
sistently show the benefit of exercise for knee pain in  older
adults (refs). Recent studies also highlight the need to pro-
vide adequate instruction, feedback and practice in order to
ensure that the key muscle groups around the knee, such as the
quadriceps, are activated (ref). The European League Against
Rheumatism (EULAR) recommendations have recently been
updated and in particular, advocate exercise for knee pain
related to osteoarthritis (ref). In line with this evidence base,
the current trial was  designed so that all participants receive a
package of care  which includes education, advice, and exercise
[41].
(iii) For this study a special ‘placebo needle’ was designed by Stre-
itberger. The needle body is  not fixed inside the copper handle.
Its tip is blunt and when it touches the skin, a  small pricking
sensation is felt by the patient, simulating the puncture of  the
skin. The handle of the needle moves over the needle, the nee-
dle  is shortened. Patients ‘see’ the needle moving inside their
body.  . . This needle was tested in 60 volunteers and proved
to be  sufficiently credible to be used in our clinical trial as a
control (ref) [51].
7.2. Item 6b
Precise description of the control or comparator. If sham
acupuncture or  any other type of acupuncture-like control is used,
provide details as for Items 1–3 above.
7.2.1. Explanation
A precise description of the components of the control or
comparator should be presented. If the control treatment is an
acupuncture-like intervention, such as a form of sham acupuncture,
then it should be specified whether the sham is invasive (pene-
trating the skin) or non-invasive (non-penetrating). The theoretical
basis, needling details and regimen of an acupuncture-like control
need to be reported in the same way as is set out in  STRICTA Items
1–3 above. The lack of a world-wide consensus on the location and
size of acupuncture points reinforces the importance of accurate
documentation of the sham points actually used, their precise loca-
tion and the method used to locate them. If usual care or  another
active treatment is  the comparator, all the components should be
reported in full detail. This will enable readers to compare usual
care as provided in the trial with what is  usually provided to par-
ticipants in  another setting. Where usual care is  also provided to
those receiving acupuncture, these data will also allow readers to
compare the intensity of usual care in  the comparator arm with that
of the experimental arm. If it is a  waitlist arm, then the period of
waiting needs to be specified. While precise description of the con-
trol or comparator is  fairly straightforward in  principle, the more
complex the components, the more care is required to  specify them
precisely.
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7.2.1.1. Examples.
(i) Acupuncturists inserted 2 needles into the sham points in  the
abdominal area, approximately 3 cm lateral to and slightly
above the umbilicus bilaterally, and then immediately applied
2  pieces of adhesive tape next to the needles. In addition,
they tapped a  mock plastic needle guiding tube on the sur-
face of each of the 9 true points in the leg to produce some
discernible sensation and then immediately applied a needle
with a piece of adhesive tape to the dermal surface, with-
out needle insertion, of each point for a  total of 20 min. The
sham acupuncture procedure was given on the same schedule
as the experimental group and used the same active needle
placements, except actual insertion did not  occur at these 9
points. Although electrical stimulation did not occur, a  mock
transelectrical stimulation unit (which emitted a  sound and
possessed a blinking light) was attached to the sham needles
at the knee. To facilitate blinding, we used screens in both treat-
ment and sham groups that were placed below the abdomen to
prevent participants from actually observing the true or sham
procedures at the knee area but to allow them to observe the
procedure being performed in  the abdomen area [21].
(ii) In each session, at least 5 out of 10 predefined distant
nonacupuncture points (ref) were needled bilaterally (at least
10 needles) and superficially using fine needles (ie, minimal
acupuncture). “De Qi” and manual stimulation of the needles
were avoided. All acupuncturists received oral instructions, a
videotape, and a  brochure with detailed information on sham
acupuncture [52].
(iii) Conservative therapy involved 10 visits to practitioners with
consultation and a prescription for diclofenac, up to  150 mg/d,
or rofecoxib, 25 mg/d, as needed until week 23 [53].
(iv) Patients received the same treatment as in the standard group
but in addition did stabilising exercises modified because
of the pregnancy (refs). The training programme started by
emphasising activation and control of local deep lumbopelvic
muscles. Training of more superficial muscles in dynamic exer-
cises to improve mobility, strength, and endurance capacity
was gradually included. Patients received treatments individ-
ually for a total of six hours during six  weeks. They were told
to integrate the exercises in  daily activities and to  exercise in
short sessions on several occasions during the day [54].
8. Discussion
This revised STRICTA Statement has been designed to  help
improve the reporting of interventions in clinical trials of acupunc-
ture, with the intention that it will help authors of acupuncture
trials provide readers with a clear, accurate and transparent
account of their acupuncture protocols as well as their control
and/or comparator procedures. In addition to revising the STRICTA
checklist, we have improved the explanations of each item  and
provided examples of good reporting. To enhance awareness,
endorsement and adherence, the revised STRICTA Statement has
been developed as an extension to  CONSORT. Authors of clinical
trials of acupuncture should use the STRICTA recommendations for
the acupuncture intervention (Item 5 in the CONSORT 2010 State-
ment) in conjunction with the other 25 items of the checklist in
the main CONSORT guidelines [10,11]. The extension to  CONSORT
for non-pharmacological interventions is  also highly relevant to
acupuncture trials [14,15].  There are other extensions to CONSORT
that may  be relevant, depending on the type of trial design, includ-
ing extensions for cluster trials, equivalence and non-inferiority
trials, and pragmatic trials, and the reporting of abstracts and of
harms (e.g. adverse events) associated with the intervention. The
Summary Points
• The Standards for Reporting Interventions in Clinical Trials
of  Acupuncture (STRICTA) were published in five journals
in 2001  and 2002. These guidelines, in the form of a check-
list and explanations for use by authors and journal editors,
were designed to improve reporting of  acupuncture tri-
als, particularly the interventions, thereby facilitating their
interpretation and replication. Subsequent reviews of  the
application and impact of STRICTA have highlighted the
value of STRICTA as well as scope for improvements and
revision.
• To manage the revision process a  collaboration between
the STRICTA Group, the CONSORT Group, and the Chinese
Cochrane Centre was developed in 2008. An expert panel
with 47  participants was convened that provided electronic
feedback on a revised draft of  the checklist. At a  subsequent
face-to-face meeting in Freiburg, a group of 21 participants
further revised the STRICTA checklist and planned dissemi-
nation.
• The new STRICTA checklist, which is an official extension of
CONSORT, includes six items and 17 sub-items. These set out
reporting guidelines for the acupuncture rationale, the details
of needling, the treatment regimen, other components of
treatment, the practitioner background, and the control or
comparator interventions. In addition, and  as part of this
revision process, the explanations for each item have been
elaborated, and examples of  good reporting for each item
are provided. In addition, the word “controlled” in STRICTA
is replaced by “clinical”, to  indicate that STRICTA is  applica-
ble  to a broad range of clinical evaluation designs, including
uncontrolled outcome studies and case reports.
• It is  intended that the revised STRICTA, in conjunction with
both the main CONSORT Statement and extension for non-
pharmacologic treatment, will raise the quality of reporting
of  clinical trials of acupuncture.
most recent versions of all CONSORT guidance documents can be
found on the CONSORT website (http://www.consort-statement.
org).
A  complete, accurate and transparent trial report facilitates
dissemination, interpretation, translation and replicability. There
continues to  be a need for better reporting generally, as has been
highlighted in a  recent study of what is  missing from descriptions
of treatments in  trials and reviews [55]. The authors found that
elements of the intervention were missing in half of the published
articles that they reviewed, giving insufficient detail, for example,
with practitioners unable to use the treatments as described and
researchers unable to  replicate studies. This finding is similar to
that from a review of authors of acupuncture trials [12].  Improved
reporting reduces reader ambiguity in  interpretation, is  likely to
increase credibility and application of the results by providing bet-
ter evidence on which to base decisions on patient care.
Reporting guidelines do help improve the quality of reporting
randomized trials [56] although it is difficult to observe their max-
imal benefit because too few journals endorse reporting guidelines
[57] and fewer adhere to  them [57].  To maximize this potential, we
encourage journals to unambiguously endorse the revised STRICTA
reporting guidelines. This can be most readily achieved by  updat-
ing journal Instructions to Authors, thereby alerting prospective
authors. In addition, we encourage journals to implement strategies
to improve author adherence to reporting guidelines. These efforts
might also help peer  reviewers and journal editors in deliberating
the merits of such trials.
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Victorin, Kien Trinh, Jorge Vas, Andrew Vickers, Peter White,
Claudia Witt, Hitoshi Yamashita, Christopher Zaslawski.
The  STRICTA Revision Group, who participated in the consensus-
building workshop in Freiburg, comprised the six  members of the
Steering Group and Stephen Birch, Isabelle Boutron, Mark Bovey, Fei
Yutong, Joel Gagnier, Sally Hopewell, Val  Hopwood, Susanne Jena,
Klaus Linde, Liu Jianping, Kien Trinh, Emma  Veitch, Adrian White,
and Hitoshi Yamashita.
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